€115 million out-licensing agreement Positive data from European confirmatory trial (PAES) Lund, Sweden, 22 July 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its half year report for the period January-June 2026. Read more…
Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. Read more…
Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The […]
· PDUFA target date set for December 19 by the FDA · Runway significantly extended Lund, Sweden, 23 April 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report January-March 2026. Read more…
Lund, Sweden, 26 March 2026. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: “2025 was a year of transformation for Hansa Biopharma, marked by the appointment of Renée Aguiar‑Lucander as our new CEO with a clear […]
